Fisher Asset Management LLC Acquires Shares of 3,786 Krystal Biotech, Inc. $KRYS

Fisher Asset Management LLC acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the 4th quarter, Holdings Channel reports. The firm acquired 3,786 shares of the company’s stock, valued at approximately $933,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Optimize Financial Inc grew its position in shares of Krystal Biotech by 1.4% during the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock worth $704,000 after buying an additional 40 shares in the last quarter. Perigon Wealth Management LLC boosted its stake in Krystal Biotech by 0.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock valued at $2,211,000 after acquiring an additional 41 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in Krystal Biotech by 2.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,124 shares of the company’s stock valued at $524,000 after acquiring an additional 55 shares during the last quarter. Sound View Wealth Advisors Group LLC grew its holdings in Krystal Biotech by 2.9% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 2,003 shares of the company’s stock worth $354,000 after acquiring an additional 56 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in Krystal Biotech by 1.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 5,896 shares of the company’s stock worth $1,454,000 after acquiring an additional 57 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $309.03 on Friday. The firm has a fifty day moving average price of $277.59 and a two-hundred day moving average price of $260.77. Krystal Biotech, Inc. has a fifty-two week low of $123.03 and a fifty-two week high of $319.48. The company has a market cap of $9.11 billion, a PE ratio of 41.31 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The firm had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Analysts expect that Krystal Biotech, Inc. will post 7.83 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $267.60, for a total value of $200,700.00. Following the completion of the transaction, the chief accounting officer owned 22,366 shares in the company, valued at approximately $5,985,141.60. This represents a 3.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 26,392 shares of company stock worth $6,974,853 in the last 90 days. Corporate insiders own 13.10% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Chardan Capital boosted their price target on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. HC Wainwright reaffirmed a “buy” rating and issued a $310.00 price target on shares of Krystal Biotech in a report on Monday, May 18th. Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup increased their target price on Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Jefferies Financial Group raised their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $324.11.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.